Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) and finished dosage formulations in the areas of feed supplements, antibiotics, anthelmintics, antibacterial, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments.
P/E ratio for Sequent Scientific Limited (SEQUENT.NS)
P/E ratio as of 2023: -84.83
According to Sequent Scientific Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -84.83. At the end of 2022 the company had a P/E ratio of -14.89.
P/E ratio history for Sequent Scientific Limited from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -84.83 |
| 2022 | -14.89 |
| 2021 | 80.83 |
| 2020 | 62.31 |
| 2019 | 27.09 |
| 2018 | 36.17 |
| 2017 | 3.60 |
| 2016 | -189.39 |
| 2015 | -119.45 |
| 2014 | -204.07 |
| 2013 | -17.91 |
| 2012 | -26.86 |
| 2011 | -1200.65 |
| 2010 | -9543.83 |
| 2009 | 43.46 |
| 2008 | -57.91 |
| 2007 | 297.58 |
| 2006 | 59.53 |